Phase II
The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.
It was a busy week for clinical trial announcements. Here’s a look.
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
Finch Therapeutics reported positive topline results from PRISM3, its Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
PRESS RELEASES